This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Jun;23(6):e236.

doi: 10.1016/S1470-2045(22)00268-6.

On the ROMANA 1 and 2 studies on anamorelin

Ulrich S Schuler¹

Affiliations

PMID: 35654053
DOI: 10.1016/S1470-2045(22)00268-6

Comment

On the ROMANA 1 and 2 studies on anamorelin

Ulrich S Schuler. Lancet Oncol. 2022 Jun.

. 2022 Jun;23(6):e236.

doi: 10.1016/S1470-2045(22)00268-6.

Author

Ulrich S Schuler¹

Affiliation

¹ University Hospital Carl Gustav Carus, D-01307 Dresden, Germany. Electronic address: ulrich.schuler@ukdd.de.

PMID: 35654053
DOI: 10.1016/S1470-2045(22)00268-6

No abstract available

PubMed Disclaimer

Conflict of interest statement

I declare no competing interests.

Comment on

Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.
Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC. Temel JS, et al. Lancet Oncol. 2016 Apr;17(4):519-531. doi: 10.1016/S1470-2045(15)00558-6. Epub 2016 Feb 20. Lancet Oncol. 2016. PMID: 26906526 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science